文献速递糖尿病

利拉鲁肽治疗的2型糖尿病患者中的淀粉酶、脂肪酶与急性胰腺炎:LEADER随机试验结果

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
PubMed 文献 · Diabetes Care · 2017-05-05

LEADER随机试验纳入9340例心血管高危的2型糖尿病患者,随机接受利拉鲁肽或安慰剂,中位观察3.84年。与安慰剂组相比,利拉鲁肽组血清脂肪酶和淀粉酶分别升高28.0%和7.0%,但急性胰腺炎事件数在数值上更少(利拉鲁肽组18例 vs 安慰剂组23例),且脂肪酶和淀粉酶升高不能预测后续急性胰腺炎风险。

要点

  • 利拉鲁肽组较安慰剂组血清脂肪酶升高28.0%、淀粉酶升高7.0%,6个月时升高后保持稳定。
  • 急性胰腺炎经裁定:利拉鲁肽组18例(0.4%,1.1事件/1000患者年)vs 安慰剂组23例(0.5%,1.7事件/1000患者年)。
  • 淀粉酶和脂肪酶升高对后续急性胰腺炎的阳性预测值<1.0%,不能预测事件风险。

核心结论

  • 在心血管高危的2型糖尿病患者中,利拉鲁肽组急性胰腺炎事件数在数值上少于安慰剂组,无论既往有无胰腺炎病史。
  • 利拉鲁肽与血清脂肪酶和淀粉酶升高相关,但这些升高不能预测后续急性胰腺炎事件。

研究设计与样本

  • LEADER随机试验,9340例心血管高危的2型糖尿病患者随机接受利拉鲁肽或安慰剂,中位观察时间3.84年,观察期3.5-5.0年。
  • 监测空腹血清脂肪酶和淀粉酶,急性胰腺炎以盲法裁定。

主要发现

  • 与安慰剂组相比,利拉鲁肽组血清脂肪酶升高28.0%,淀粉酶升高7.0%。
  • 脂肪酶和淀粉酶水平在6个月时升高,之后保持稳定。
  • 研究期间,利拉鲁肽组18例(0.4%[1.1事件/1000患者年])和安慰剂组23例(0.5%[1.7事件/1000患者年])经裁定确诊急性胰腺炎。
  • 多数急性胰腺炎病例发生在随机化后≥12个月。
  • 有胰腺炎病史的利拉鲁肽组患者(n=147)与安慰剂组相似患者(n=120)相比,发生急性胰腺炎的可能性未增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3.5-5.0 years. RESEARCH DESIGN AND METHODS: A total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years). Fasting serum lipase and amylase were monitored. Acute pancreatitis was adjudicated in a blinded manner. RESULTS: Compared with the placebo group, liraglutide-treated patients had increases in serum lipase and amylase of 28.0% and 7.0%, respectively. Levels were increased at 6 months and then remained stable. During the study, 18 (0.4% [1.1 events/1,000 patient-years of observation] [PYO]) liraglutide-treated and 23 (0.5% [1.7 events/1,000 PYO]) placebo patients had acute pancreatitis confirmed by adjudication. Most acute pancreatitis cases occurred ≥12 months after randomization. Liraglutide-treated patients with prior history of pancreatitis (n = 147) were not more likely to develop acute pancreatitis than similar patients in the placebo group (n = 120). Elevations of amylase and lipase levels did not predict future risk of acute pancreatitis (positive predictive value <1.0%) in patients treated with liraglutide. CONCLUSIONS: In a population with type 2 diabetes at high cardiovascular risk, there were numerically fewer events of acute pancreatitis among liraglutide-treated patients (regardless of previous history of pancreatitis) compared with the placebo group. Liraglutide was associated with increases in serum lipase and amylase, which were not predictive of an event of subsequent acute pancreatitis.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Steinberg WM, Buse JB, Ghorbani MLM, et al. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 2017. PMID: 28476871. doi:10.2337/dc16-2747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。